DDInter298 DDInter1628
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Carboplatin {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is associated with {v} (Gene) MAP3K3
MAP3K3 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Carboplatin {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) downregulates {v} (Gene) AKAP8
AKAP8 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is associated with {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Carboplatin {u} (Compound) treats {v} (Disease) urinary bladder cancer
urinary bladder cancer {u} (Disease) is associated with {v} (Gene) POLB
POLB {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Carboplatin {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) downregulates {v} (Gene) LETMD1
LETMD1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Carboplatin {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) is downregulated by {v} (Disease) and {u} (Disease) associated with {v} (Gene) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) regulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Carboplatin {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) downregulates {v} (Gene) DCLK1
DCLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Carboplatin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Ruxolitinib (Compound)
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is associated with MAP3K3 (Gene) and MAP3K3 (Gene) is bound by Ruxolitinib (Compound)
Carboplatin (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) downregulates AKAP8 (Gene) and AKAP8 (Gene) is upregulated by Ruxolitinib (Compound)
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is associated with PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Carboplatin (Compound) treats urinary bladder cancer (Disease) and urinary bladder cancer (Disease) is associated with POLB (Gene) and POLB (Gene) is downregulated by Ruxolitinib (Compound)
Carboplatin (Compound) treats breast cancer (Disease) and breast cancer (Disease) downregulates LETMD1 (Gene) and LETMD1 (Gene) is downregulated by Ruxolitinib (Compound)
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Carboplatin (Compound) binds MPO (Gene) and MPO (Gene) is downregulated by hematologic cancer (Disease) and MPO (Disease) associated with hematologic cancer (Gene) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) regulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Ruxolitinib (Compound)
Carboplatin (Compound) treats breast cancer (Disease) and breast cancer (Disease) downregulates DCLK1 (Gene) and DCLK1 (Gene) is bound by Ruxolitinib (Compound)